Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization
Coronary Artery Disease(CAD)
About this trial
This is an interventional treatment trial for Coronary Artery Disease(CAD) focused on measuring coronary artery disease, revascularization, Danlou Tablet
Eligibility Criteria
Inclusion Criteria:
- Participants are aged between 45 and 75 years, diagnosed with sever CAD through coronary arteriography which shows that the left main coronary artery and three-vessel have sever diffuse stenosis, calcification or vascular ectasia, be in accordance with Traditional Chinese Medicine syndrome of "Qi deficiency and blood stasis syndrome" or "phlegm and stasis mu-tual obstruction syndrome".
Exclusion Criteria:
- Patients with severe valvular disease, congenital cardiomyopathy decompensation
- Patients with CAD complicated with severe multiple organ disease such as severe heart failure, severe lung, liver or renal dysfunction, peptic ulcer in active stage, or intracranial hemorrhage
- Patients that use high-dose steroids due to connective tissue disease
- Patients with serious infections
- Patients with malignant tumor
- Patients with hematopoietic diseases
- Pregnant or lactating women.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Danlou Tablet
Danlou Tablet placebo
Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)
Placebo Danlou 0.3g tablet by mouth, 5 tablets three times daily for 6 months & conventional western medicine (including Aspirin Enteric-coated Tablets, Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet, Atorvastatin Calcium, Isosorbide Mononitrate Tab 20 MG, Metoprolol Tartrate Tab 25 MG, Trimetazidine Dihydrochloride Tablets)